These included, YAP1, IPO7, CDC42, LAMB1, LAMC1, KRT16 and GLS higher expression was associated with lower survival in MSS patients (Fig. S13) (OS: YAP1 HR 1·7, pval = 0·000088; IPO7 HR 1·37, pval = 0·059; CDC42 HR 1·73, pval = 3e-04; LAMB1 HR 2·39, pval = 0·00081; LAMC1 HR 2·37, pval = 0·00052, KRT16 HR 1·58, pval = 0·0038; GLS HR 1·67, pval = 0·00083), while for ACAT1 there was an effect on relapse-free survival in advanced stages (1·51, pval = 0·027) (Fig. S14). Here, KRT16 is linked to Marinesco-Sjogren syndrome.